Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
Biologic treatments have revolutionised the management of psoriasis in recent years; however, data on their safety profile in large populations and long-term effects are being gathered on an ongoing basis. Ustekinumab is a monoclonal antibody that targets interleukin-12/23 used in the treatment of m...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Dermatological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/8868553 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546939629993984 |
|---|---|
| author | Bayanne Olabi Shanti Ayob |
| author_facet | Bayanne Olabi Shanti Ayob |
| author_sort | Bayanne Olabi |
| collection | DOAJ |
| description | Biologic treatments have revolutionised the management of psoriasis in recent years; however, data on their safety profile in large populations and long-term effects are being gathered on an ongoing basis. Ustekinumab is a monoclonal antibody that targets interleukin-12/23 used in the treatment of moderate-to-severe psoriasis. Here, we report the case of a 32-year-old Caucasian gentleman who developed thyrotoxicosis following the commencement of ustekinumab treatment. Following control of thyroid status by the Endocrinology team, this recurred after recommencement of ustekinumab on two further occasions over a 5-year period. This is the second known reported association of this nature. Awareness of these possible adverse effects is imperative in managing patients and informing decision-making, and further long-term studies will help elucidate the precise safety profiles of biologic treatments. |
| format | Article |
| id | doaj-art-5027a9c8e49341f29668e9e418815b46 |
| institution | Kabale University |
| issn | 2090-6463 2090-6471 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Dermatological Medicine |
| spelling | doaj-art-5027a9c8e49341f29668e9e418815b462025-02-03T06:46:35ZengWileyCase Reports in Dermatological Medicine2090-64632090-64712020-01-01202010.1155/2020/88685538868553Thyrotoxicosis Associated with Ustekinumab Treatment for PsoriasisBayanne Olabi0Shanti Ayob1Department of Dermatology, Lauriston Building, Edinburgh EH3 9EN, UKDepartment of Dermatology, NHS Treatment Centre, Nottingham NG7 2FT, UKBiologic treatments have revolutionised the management of psoriasis in recent years; however, data on their safety profile in large populations and long-term effects are being gathered on an ongoing basis. Ustekinumab is a monoclonal antibody that targets interleukin-12/23 used in the treatment of moderate-to-severe psoriasis. Here, we report the case of a 32-year-old Caucasian gentleman who developed thyrotoxicosis following the commencement of ustekinumab treatment. Following control of thyroid status by the Endocrinology team, this recurred after recommencement of ustekinumab on two further occasions over a 5-year period. This is the second known reported association of this nature. Awareness of these possible adverse effects is imperative in managing patients and informing decision-making, and further long-term studies will help elucidate the precise safety profiles of biologic treatments.http://dx.doi.org/10.1155/2020/8868553 |
| spellingShingle | Bayanne Olabi Shanti Ayob Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis Case Reports in Dermatological Medicine |
| title | Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis |
| title_full | Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis |
| title_fullStr | Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis |
| title_full_unstemmed | Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis |
| title_short | Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis |
| title_sort | thyrotoxicosis associated with ustekinumab treatment for psoriasis |
| url | http://dx.doi.org/10.1155/2020/8868553 |
| work_keys_str_mv | AT bayanneolabi thyrotoxicosisassociatedwithustekinumabtreatmentforpsoriasis AT shantiayob thyrotoxicosisassociatedwithustekinumabtreatmentforpsoriasis |